Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant (CHARMS)
Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant
Sponsor: AlloVir
Listed as NCT02108522, this NA trial focuses on Infection and remains completed. Sponsored by AlloVir, it has been updated 16 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Dec 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 11 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed NA
-
Jan 2021 — Sep 2021 [monthly]
Completed NA
-
Feb 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
-
Jun 2019 — Nov 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Jun 2019 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jun 2017 — Oct 2017 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AlloVir
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .